Company Overview and News

 
Williams' Atlantic Sunrise Pipeline Seeks Final Nod From FERC

2018-09-20 zacks
Williams Companies, Inc. (WMB - Free Report) recently reported the completion of construction of its major Atlantic Sunrise project. The production and pipeline operator has requested for the final approval of the project by Federal Energy Regulatory Commission (FERC), post which the pipeline will come into service. Importantly, the Atlantic Sunrise natural gas pipeline, worth $3 billion, is an expansion of the company’s Transco pipeline, which is the largest-volume natural gas transmission system in the United States.
HLX TCP WMB

10
AltaGas: Abandoning Canada, Will The Company Win Over U.S. Investors?

2018-09-17 seekingalpha
AltaGas has been consistently investing in U.S. projects over Canadian ones. Recent divestitures to fund the U.S. based WGL Holdings acquisition have tilted Canadian.
SOJA DUKH SO TRP SCG WGL DTK DUK ENB ENB ATGFF EQT WMB TRP ED PBA

 
Williams Companies: Expensive Price Worth The Lower Risk?

2018-09-13 seekingalpha
Natural gas midstreams are currently cheaper than their oil counterparts - certainly alluring given the long-term appeal of natural gas.
WPZ WMB

 
WMB / Williams Companies, Inc. (The) / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov
SCHEDULE 13G Amendment No. 3 WILLIAMS COS INC COMMON STOCK Cusip #969457100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #969457100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,888,797 Item 6: 0 Item 7: 32,241,692 Item 8: 0 Item 9: 32,241,692 Item 11: 2.663% Item 12: HC Cusip #969457100 Item 1: Reporting Person - Abigail P.
WMB

 
WMB / Williams Companies, Inc. (The) / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov
SCHEDULE 13G Amendment No. 3 WILLIAMS COS INC COMMON STOCK Cusip #969457100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #969457100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,888,797 Item 6: 0 Item 7: 32,241,692 Item 8: 0 Item 9: 32,241,692 Item 11: 2.663% Item 12: HC Cusip #969457100 Item 1: Reporting Person - Abigail P.
WMB

94
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 1
Glenview Capital Management's 13F portfolio value decreased from $17.10B to $14.66B this quarter. The number of positions decreased from 52 to 49.
LOW ATHTF FLEX LBTY WBA ENL CVS HPE SHPG NWL LBTYK LILAB WMB DOW MTOR CAH DXC AET CMCSK IQV EBAY MIK TMUSP TMUS BKD CBS.WD VER CNDT GOOGL LILAK RLGY MSFT CPV MHK ENDP FB PAH TMO CCV MCK CCZ GOOG DLPH CHTR AGN DXC.WI CI ARMK HOLX CBS CSC CBS.A CMCSA FTI.WI FMC LBTYB LBTYA FDX ANTM HUM DWDP ABC V CCV.CL FDC THC APTV ANTX LILA

134
Tracking David Tepper's Appaloosa Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 9
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
PCG LRCX SYMC KMT CQP CNC VST XOP KEY NRGEO CFIN WPZ BSX CIWV HCA SYK AABA AMAT WMB SUM BTUUQ VNTR BAC TMUSP LNG TMUS OC NRG ALL BABA ETP CZR GOOGL WMIH TERP WFCNP MGM FB PAH AY TMO WDC NVDA GOOG BAC HUN AGN UBS WFC WMIHP GJT XPO CFG BTU ALLY MU VSTE URI DG ULSGF

13
Midstream Out Of Office Washout

2018-09-02 seekingalpha
Midstream had a rough week, the worst since late March and 4th worst so far this year. Oil prices rallied for a second straight week, NGL prices were sharply higher, the broad stock market was higher again, but midstream and MLPs lagged badly.
NGL CCR TGE ENB CEQP GNE EQM KMI TRP WMB AMGP OKE ED KMR CVB GEL NEE TRP VLP RGCO ENB ETP GNE TRGP PBA KMRFZ

 
Gulfport Energy (GPOR) Up 3.9% Since Last Earnings Report: Can It Continue?

2018-09-01 zacks
It has been about a month since the last earnings report for Gulfport Energy (GPOR - Free Report) . Shares have added about 3.9% in that time frame, outperforming the S&P 500.
GPOR WMB

1
Exelixis (EXEL) Down 14.1% Since Last Earnings Report: Can It Rebound?

2018-09-01 zacks - 1
A month has gone by since the last earnings report for Exelixis (EXEL - Free Report) . Shares have lost about 14.1% in that time frame, underperforming the S&P 500.
RHHVF EXEL GPOR WMB RHHBY RHHBF

2
Why Is Lincoln National (LNC) Up 0.2% Since Last Earnings Report?

2018-09-01 zacks - 1
A month has gone by since the last earnings report for Lincoln National (LNC - Free Report) . Shares have added about 0.2% in that time frame, underperforming the S&P 500.
LNC GPOR WMB

 
Williams Companies, Inc. (WMB) Down 4.2% Since Last Earnings Report: Can It Rebound?

2018-08-31 zacks
A month has gone by since the last earnings report for Williams Companies, Inc. (WMB - Free Report) . Shares have lost about 4.2% in that time frame, underperforming the S&P 500.
SGMS WMB

2
MLP Monthly Report: August 2018

2018-08-28 seekingalpha
The August MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
KKR SNSR MLPA AND LIT ETE BFIT GXG SIL KRMA GXF CHII EV ACTX CHIE GOEX FINX WMB CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI ETP LNGR COPX QQQC GURU

17
Big Changes This Summer, Little Changed This Week

2018-08-27 seekingalpha
This week, Midstream stocks were little changed and basically kept pace with the S&P 500, which hit a new all-time high for the first time since January. Midstream stocks didn't get additional lift from the first positive week for oil prices in two months, but it certainly didn't hurt. Trading volume was light across midstream, with a few exceptions, and should be even lighter next week.
TGE CQP ENB WGP IPL SEP HCLP CEQP OKE.WI KMI TRP WMB EQGP AMGP EBBNF OKE KMR FGP IPPLF CVB ENBBF TRP GEIG ENB GMLP SEMG TRGP PBA KMRFZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to WMB / Williams Companies, Inc. (The) on message board site Silicon Investor.

Williams Companies, Inc. (WMB) Williams Companies, Inc. (WMB) Williams Companies, Inc. (WMB) WILLIAMS CO. WILLIAMS CO. WILLIAMS CO.
CUSIP: 969457100